Dolutegravir for the treatment of HIV-2 infection.
BACKGROUND
Therapeutic options are limited for HIV-2 infected persons, largely in part due to the lack of susceptibility to HIV-1 non-nucleoside reverse transcriptase inhibitors and poor susceptibility to some HIV-1 protease inhibitors. This is particularly worrisome for HIV-2 patients with prior antiretroviral failure.


OBJECTIVE
Report the virological response to dolutegravir in HIV-2-infected individuals.


METHODS
Retrospective observational assessment of all HIV-2 individuals treated with dolutegravir in Spain.


RESULTS
From 297 HIV-2-infected individuals recorded at the Spanish national registry, 26% received antiretroviral therapy. Six out of 8 failing on raltegravir selected for integrase resistance mutations N155H (4), Y143G (1) and Q148R (1). Two patients bearing N155H subsequently received dolutegravir. Both experienced initially more than 1.5 log drop in plasma HIV-2 RNA and significant CD4 gains. Whereas one kept on undetectable viremia 6 months later, the other experienced viral rebound.


CONCLUSIONS
Dolutegravir may be a good therapeutic option for patients with HIV-2 infection, including those that previously failed other integrase inhibitors.
Laboratory of Virology, Puerta de Hierro Research Institute and University Hospital, Majadahonda, Madrid, Spain.
Ana
A
Treviño
Hospital de Poniente, Almeria, Spain.
Teresa
T
Cabezas
Hospital de Poniente, Almeria, Spain.
Ana Belén
AB
Lozano
Fundación Jimenez Díaz, Madrid, Spain.
Rosa
R
García-Delgado
Hospital de Mataró, Barcelona, Spain.
Luis
L
Force
Hospital de Poniente, Almeria, Spain.
José María
JM
Fernández-Montero
Laboratory of Virology, Puerta de Hierro Research Institute and University Hospital, Majadahonda, Madrid, Spain. Electronic address: cmendoza.cdm@gmail.com.
Carmen de
Cd
Mendoza
Hospital Vall d'Hebrón, Barcelona, Spain.
Estrella
E
Caballero
Infectious Diseases Unit, La Paz University Hospital & IdiPAZ, Paseo de la Castellana 261, Madrid 28046, Spain. Electronic address: vsoriano@dragonet.es.
Vincent
V
Soriano
D000328:Adult; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D019428:HIV Integrase Inhibitors / Q000627:therapeutic use*; D015498:HIV-2 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006575:Heterocyclic Compounds, 3-Ring / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009154:Mutation; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000068898:Raltegravir Potassium / Q000627:therapeutic use*; D012189:Retrospective Studies; D013030:Spain; D014766:Viremia; D000099226:Dolutegravir
D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000068898:Raltegravir Potassium; D000099226:Dolutegravir
Antiretroviral therapy; Dolutegravir; Drug resistance; HIV-2; Raltegravir